Semaglutide vs Dulaglutide: A Research Literature Comparison (SUSTAIN vs AWARD Trials)

Research Use Only: Semaglutide and dulaglutide products sold by Loti Labs are laboratory research compounds intended strictly for in-vitro and animal-model research by qualified investigators. They are not FDA-approved, not for human consumption, and not a substitute for an approved medication. This article summarizes published clinical-trial literature on the branded, FDA-approved versions of these molecules for scientific and regulatory context only — it is not medical advice and does not describe a use case for any Loti Labs product.

Introduction to GLP-1 Receptor Agonists in the Literature

Semaglutide and dulaglutide are both classified as GLP-1 receptor agonists, a drug class that has been extensively studied in the peer-reviewed literature for its effects on glycemic control and body weight in type 2 diabetes trial populations. This post summarizes published research comparing the two molecules — their mechanism, trial-reported outcomes, and safety signals — as documented in the SUSTAIN and AWARD clinical trial programs run by their respective manufacturers.

Mechanism of Action: How GLP-1 Receptor Agonists Work

GLP-1 receptor agonists mimic the endogenous incretin hormone GLP-1. In published pharmacology literature, this class of molecule increases glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying. These combined mechanisms are the basis for the glycemic and body-weight effects reported across the trial literature discussed below. Preclinical and translational research continues to characterize the downstream signaling pathways involved, including effects on pancreatic beta-cell biology reported in animal models.

Semaglutide and Dulaglutide in Regulatory Context

The branded, FDA-approved formulations of semaglutide and dulaglutide are approved prescription medications, available only through a licensed prescriber. The research-grade compounds referenced in the scientific literature — and any compound sold by Loti Labs under a Research Use Only designation — are not the approved drug product, are not reviewed or approved by the FDA for any use, and are restricted to laboratory and preclinical research settings.

SUSTAIN Trials: Published Semaglutide Findings

The SUSTAIN trial program, sponsored by the manufacturer of semaglutide, is a series of randomized controlled trials that formed part of the regulatory submission supporting FDA approval of the branded drug. Across the published SUSTAIN literature, semaglutide arms reported HbA1c reductions exceeding 1.5% along with weight-change outcomes, with study designs controlling for baseline age, diabetes duration, and BMI. The SUSTAIN 7 trial, published in The Lancet Diabetes & Endocrinology, directly compared semaglutide with dulaglutide and reported larger mean reductions in both HbA1c and body weight for the semaglutide arm.

AWARD Trials: Published Dulaglutide Findings

The AWARD trial program similarly supported the regulatory approval of dulaglutide. Published AWARD data report HbA1c reductions in the 1.5%–1.9% range for trial participants receiving dulaglutide, along with body-weight changes documented across the six-study program. In five of the six published AWARD studies, the higher dulaglutide dose arm reached a larger proportion of prespecified HbA1c targets relative to comparator arms. Investigators recorded baseline blood pressure and other covariates to support between-group comparisons.

Comparative Effectiveness Methods in the Literature

Because SUSTAIN and AWARD did not always test the two molecules head-to-head, published meta-research has applied indirect treatment comparison and network meta-regression methods to compare HbA1c and weight-change outcomes across the two trial programs. These statistical approaches, along with bibliometric analysis of the growing semaglutide and dulaglutide literature since 2014, help researchers identify consistent findings and remaining evidence gaps — including a continued lack of controlled trial data in pediatric, postpartum, and lactating populations.

Trial-Reported Dosing Regimens (Historical/Literature Context Only)

For reference, the branded semaglutide trials used a once-weekly subcutaneous regimen starting at 0.25 mg and titrated to 0.5 mg and then 1 mg weekly under prescriber supervision, while the AWARD dulaglutide trials used a once-weekly regimen starting at 0.75 mg and titrated to 1.5 mg weekly. These figures describe the design of the cited published trials of the approved prescription drug and are provided for scientific-literature context only. They are not administration instructions and do not apply to any Loti Labs research compound, which is not approved for use in humans or animals outside a qualified research protocol.

Reported Safety Signals in the Trial Literature

The published trial literature reports gastrointestinal adverse events (most commonly nausea and other digestive symptoms) as the most frequent reason for treatment discontinuation across both trial programs, with a numerically higher discontinuation rate in dulaglutide arms in several studies. Semaglutide trial data additionally report a signal for diabetic retinopathy complications not carried by dulaglutide in the same literature. These are summaries of published trial safety reporting for the approved drug, not a safety profile for any research compound sold by Loti Labs.

Research and Development Insights

Published research volume on semaglutide and dulaglutide has grown substantially since 2014, with publication counts peaking in 2022 alongside expanding interest in GLP-1 receptor agonist pharmacology, including cardiovascular and metabolic research directions. Animal-model studies continue to investigate downstream mechanisms such as beta-cell preservation signaling, though translational relevance to human physiology remains an open research question requiring further controlled study.

Summary

Semaglutide and dulaglutide are both GLP-1 receptor agonists with a substantial published clinical-trial literature base (SUSTAIN and AWARD, respectively) supporting their FDA-approved use as prescription medications. Comparative literature generally reports larger HbA1c and body-weight effects for semaglutide, with a different gastrointestinal tolerability profile for dulaglutide. Products sold by Loti Labs referencing these molecules are Research Use Only laboratory compounds, are not the approved drug product, and are not intended for human or animal use outside a qualified research setting.

Frequently Asked Questions

Are Loti Labs’ semaglutide or dulaglutide research compounds the same as the prescription drugs discussed in this article?
No. This article summarizes published literature on the FDA-approved prescription drugs. Loti Labs sells only Research Use Only laboratory compounds, which are not approved by the FDA and are not intended for human or animal use outside qualified research settings.

What did the SUSTAIN and AWARD trials measure?
Both trial programs measured HbA1c reduction and body-weight change as primary and secondary endpoints, among other safety and tolerability measures, in randomized controlled trial populations with type 2 diabetes.

Is this article medical advice?
No. This content is a summary of publicly available clinical-trial literature for scientific and regulatory reference only and does not constitute medical advice or a recommendation for any product or use.

References

Pratley, R. E., et al. (2018). “Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7).” The Lancet Diabetes & Endocrinology, 6(4), 275–286.